TechTarget

techtarget.com

TechTarget (Nasdaq: TTGT) is the global leader in purchase intent-driven marketing and sales services that deliver business impact for enterprise technology companies. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies’ information technology needs. By understanding these buyers’ content consumption behaviors, TechTarget creates the purchase intent insights that fuel efficient and effective marketing and sales activities for clients around the world.

C-Suite On Deck

John A. Steinert, Chief Marketing Officer at TechTarget helps bring the power of purchase intent-driven marketing and sales services to technology companies.

With a strong drive to help customers achieve their business objectives faster and bigger, John and his TechT...

Events

Related News

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

news image

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More

VIEWS AND ANALYSIS

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

news image

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More

BUSINESS INSIGHTS

BD COMPLETES ACQUISITION OF PARATA SYSTEMS

BD | July 19, 2022

news image

BD announced it has completed the acquisition of Parata Systems. Parata advances BD's transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies. As a combined company, BD is positioned to offer a comprehensive set of technologies to the $600 million pharmacy automati...

Read More
news image

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More
news image

VIEWS AND ANALYSIS

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More
news image

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More
news image

BUSINESS INSIGHTS

BD COMPLETES ACQUISITION OF PARATA SYSTEMS

BD | July 19, 2022

BD announced it has completed the acquisition of Parata Systems. Parata advances BD's transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies. As a combined company, BD is positioned to offer a comprehensive set of technologies to the $600 million pharmacy automati...

Read More

Resources

Events

C-Suite On Deck

John A. Steinert, Chief Marketing Officer at TechTarget helps bring the power of purchase intent-driven marketing and sales services to technology companies.

With a strong drive to help customers achieve their business objectives faster and bigger, John and his TechT...